ACON
Aclarion, Inc. Common Stock
Latest price
As of Oct 30, 2026, 6:30 PM EDT · Market data by Massive
Market cap
$5.6M
Volume
18.5K
Previous close
$1.97
Day range
$1.88 – $2.00
Listed
Apr 22, 2022
Coverage
14 articles
Price performance
Recent trading
Newsroom
Latest ACON coverage
Aclarion Announces Closing of $3.0 Million Public Offering
[ad_1] BROOMFIELD, CO – (NewMediaWire) – February 27, 2024 – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced the closing of its
Aclarion Announces Pricing of $3.0 Million Public Offering
[ad_1] BROOMFIELD, CO – (NewMediaWire) – February 26, 2024 – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced the pricing of its
Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution
[ad_1] Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine This new product release expands accessibility of Nociscan on the worldwide MR market Builds on preexisting compatibility with Siemens BROOMFIELD, CO – (NewMediaWire) – January 17, 2024 – Aclarion, Inc., (“Aclarion” or the “Company”)
Aclarion Announces Reverse Stock Split
[ad_1] BROOMFIELD, CO – (NewMediaWire) – January 2, 2024 – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that effective befor
Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams
[ad_1] Pace of Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans Further acceleration of scan volumes expected as MRIs are activated for the recently completed panel of 10 Key Opinion Leader (KOL) surgeons All commercial Nociscans to date have been completed on Siemens MRI scanners with additional acceleration ...
Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report
[ad_1] BROOMFIELD, CO – (NewMediaWire) – August 25, 2023 – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it was not abl
Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI
[ad_1] BROOMFIELD, CO – (NewMediaWire) – June 14, 2023 – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their commercial agree
Aclarion Announces Statistically Significant Nociscan Cost-Effectiveness Abstract Presented at ISASS Annual Meeting
[ad_1] Nociscan cost-effectiveness abstract highlights dominance over provocative discography and can save the US healthcare system $283M to $441M annually. The International Society for the Advancement of Spine Surgery (ISASS) Annual Meeting was held June 1-3, 2023. ISASS Policy Statement on Lumbar Spinal Fusion Surgery acknowledges MR Spectroscopy as an ef
Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts
[ad_1] Up to $2M Unsecured, Non-Convertible Bridge Debt With No Required Amortization Payments Financing Supports Execution of the 2023 Plan and the Achievement of Critical Milestones in Support of Definitive Growth Capital BROOMFIELD, CO – (NewMediaWire) – May 19, 2023 – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),
Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023
[ad_1] Nociscan™ is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological low back pain. Nociscan provides decision support to help bridge a major diagnostic void. Sigurd Berven, MD will speak to groundbreaking clinical and economic evidence of Nociscan. Jeff Lotz, PhD will speak to the foundati
Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium
[ad_1] NociscanTM is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain. Nociscan provides decision support to help bridge a major diagnostic void. Robert Eastlack, MD will speak to his real-world experience using Nociscan to effectively evaluate CLBP. BROOMFIELD, CO – (NewM
Aclarion's Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD
[ad_1] Development of this program supports Aclarion’s commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy. Broomfield, CO – (NewMediaWire) – December 21, 2022 – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveragi
Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor
[ad_1] Broomfield, CO – (NewMediaWire) – December 22, 2022 – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Dr. Christop
Aclarion Adds to Growing Key Opinion Leader Program with Juan Uribe M.D. as a Surgeon Advisor
[ad_1] Dr. Uribe is the fourth national KOL to join the Aclarion team this year. Development of this program supports Aclarion’s commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy. Broomfield, CO – (NewMediaWire) – December 19, 2022 – Aclarion, Inc., (“Aclarion” or the “Compa